SYK vs. TEVA: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at SYK and TEVA, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
SYK is a standard domestic listing, while TEVA trades as an American Depositary Receipt (ADR), offering U.S. investors access to its foreign-listed shares.
| Symbol | SYK | TEVA |
|---|---|---|
| Company Name | Stryker Corporation | Teva Pharmaceutical Industries Limited |
| Country | United States | Israel |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Equipment & Supplies | Pharmaceuticals |
| Market Capitalization | 138.01 billion USD | 29.08 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | March 17, 1980 | February 16, 1982 |
| Security Type | Common Stock | ADR |
Historical Performance
This chart compares the performance of SYK and TEVA by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | SYK | TEVA |
|---|---|---|
| 5-Day Price Return | 2.03% | 2.64% |
| 13-Week Price Return | -5.16% | 49.95% |
| 26-Week Price Return | -6.53% | 35.82% |
| 52-Week Price Return | -6.73% | 11.38% |
| Month-to-Date Return | 1.68% | 25.16% |
| Year-to-Date Return | 0.60% | 1.75% |
| 10-Day Avg. Volume | 2.03M | 2.76M |
| 3-Month Avg. Volume | 1.41M | 2.04M |
| 3-Month Volatility | 20.46% | 44.05% |
| Beta | 0.89 | 1.10 |
Profitability
Return on Equity (TTM)
SYK
13.92%
Health Care Equipment & Supplies Industry
- Max
- 29.82%
- Q3
- 15.54%
- Median
- 9.69%
- Q1
- 5.19%
- Min
- -7.98%
SYK’s Return on Equity of 13.92% is on par with the norm for the Health Care Equipment & Supplies industry, indicating its profitability relative to shareholder equity is typical for the sector.
TEVA
-2.58%
Pharmaceuticals Industry
- Max
- 38.95%
- Q3
- 20.34%
- Median
- 11.59%
- Q1
- 3.32%
- Min
- -10.91%
TEVA has a negative Return on Equity of -2.58%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
SYK
12.07%
Health Care Equipment & Supplies Industry
- Max
- 24.65%
- Q3
- 14.10%
- Median
- 10.09%
- Q1
- 5.84%
- Min
- -6.13%
SYK’s Net Profit Margin of 12.07% is aligned with the median group of its peers in the Health Care Equipment & Supplies industry. This indicates its ability to convert revenue into profit is typical for the sector.
TEVA
-0.95%
Pharmaceuticals Industry
- Max
- 39.07%
- Q3
- 19.28%
- Median
- 13.48%
- Q1
- 5.73%
- Min
- -8.86%
TEVA has a negative Net Profit Margin of -0.95%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
SYK
15.04%
Health Care Equipment & Supplies Industry
- Max
- 31.34%
- Q3
- 18.36%
- Median
- 15.07%
- Q1
- 9.62%
- Min
- -0.13%
SYK’s Operating Profit Margin of 15.04% is around the midpoint for the Health Care Equipment & Supplies industry, indicating that its efficiency in managing core business operations is typical for the sector.
TEVA
5.38%
Pharmaceuticals Industry
- Max
- 45.58%
- Q3
- 24.35%
- Median
- 18.05%
- Q1
- 7.58%
- Min
- -11.88%
TEVA’s Operating Profit Margin of 5.38% is in the lower quartile for the Pharmaceuticals industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.
Profitability at a Glance
| Symbol | SYK | TEVA |
|---|---|---|
| Return on Equity (TTM) | 13.92% | -2.58% |
| Return on Assets (TTM) | 6.46% | -0.40% |
| Net Profit Margin (TTM) | 12.07% | -0.95% |
| Operating Profit Margin (TTM) | 15.04% | 5.38% |
| Gross Profit Margin (TTM) | 64.59% | 50.88% |
Financial Strength
Current Ratio (MRQ)
SYK
1.85
Health Care Equipment & Supplies Industry
- Max
- 4.97
- Q3
- 2.92
- Median
- 2.12
- Q1
- 1.54
- Min
- 0.86
SYK’s Current Ratio of 1.85 aligns with the median group of the Health Care Equipment & Supplies industry, indicating that its short-term liquidity is in line with its sector peers.
TEVA
1.06
Pharmaceuticals Industry
- Max
- 5.45
- Q3
- 2.99
- Median
- 1.98
- Q1
- 1.29
- Min
- 0.78
TEVA’s Current Ratio of 1.06 falls into the lower quartile for the Pharmaceuticals industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
SYK
0.68
Health Care Equipment & Supplies Industry
- Max
- 1.62
- Q3
- 0.74
- Median
- 0.47
- Q1
- 0.15
- Min
- 0.00
SYK’s Debt-to-Equity Ratio of 0.68 is typical for the Health Care Equipment & Supplies industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
TEVA
2.52
Pharmaceuticals Industry
- Max
- 1.79
- Q3
- 0.78
- Median
- 0.31
- Q1
- 0.08
- Min
- 0.00
With a Debt-to-Equity Ratio of 2.52, TEVA operates with exceptionally high leverage compared to the Pharmaceuticals industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
Interest Coverage Ratio (TTM)
SYK
14.59
Health Care Equipment & Supplies Industry
- Max
- 56.35
- Q3
- 24.86
- Median
- 9.84
- Q1
- 3.86
- Min
- -21.65
SYK’s Interest Coverage Ratio of 14.59 is positioned comfortably within the norm for the Health Care Equipment & Supplies industry, indicating a standard and healthy capacity to cover its interest payments.
TEVA
-0.38
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 43.60
- Median
- 10.15
- Q1
- 2.37
- Min
- -42.71
TEVA has a negative Interest Coverage Ratio of -0.38. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | SYK | TEVA |
|---|---|---|
| Current Ratio (MRQ) | 1.85 | 1.06 |
| Quick Ratio (MRQ) | 0.94 | 0.68 |
| Debt-to-Equity Ratio (MRQ) | 0.68 | 2.52 |
| Interest Coverage Ratio (TTM) | 14.59 | -0.38 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
SYK
0.92%
Health Care Equipment & Supplies Industry
- Max
- 4.36%
- Q3
- 1.87%
- Median
- 0.82%
- Q1
- 0.00%
- Min
- 0.00%
SYK’s Dividend Yield of 0.92% is consistent with its peers in the Health Care Equipment & Supplies industry, providing a dividend return that is standard for its sector.
TEVA
0.00%
Pharmaceuticals Industry
- Max
- 6.72%
- Q3
- 3.48%
- Median
- 1.90%
- Q1
- 0.00%
- Min
- 0.00%
TEVA currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
SYK
43.09%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 67.77%
- Median
- 28.21%
- Q1
- 0.00%
- Min
- 0.00%
SYK’s Dividend Payout Ratio of 43.09% is within the typical range for the Health Care Equipment & Supplies industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
TEVA
0.00%
Pharmaceuticals Industry
- Max
- 199.58%
- Q3
- 85.87%
- Median
- 49.36%
- Q1
- 1.12%
- Min
- 0.00%
TEVA has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | SYK | TEVA |
|---|---|---|
| Dividend Yield (TTM) | 0.92% | 0.00% |
| Dividend Payout Ratio (TTM) | 43.09% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
SYK
46.83
Health Care Equipment & Supplies Industry
- Max
- 67.59
- Q3
- 41.41
- Median
- 33.11
- Q1
- 22.82
- Min
- 8.68
A P/E Ratio of 46.83 places SYK in the upper quartile for the Health Care Equipment & Supplies industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.
TEVA
--
Pharmaceuticals Industry
- Max
- 52.64
- Q3
- 29.89
- Median
- 20.77
- Q1
- 13.37
- Min
- 5.71
P/E Ratio data for TEVA is currently unavailable.
Price-to-Sales Ratio (TTM)
SYK
5.65
Health Care Equipment & Supplies Industry
- Max
- 9.49
- Q3
- 5.41
- Median
- 2.92
- Q1
- 1.97
- Min
- 0.61
SYK’s P/S Ratio of 5.65 is in the upper echelon for the Health Care Equipment & Supplies industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
TEVA
1.80
Pharmaceuticals Industry
- Max
- 8.74
- Q3
- 4.66
- Median
- 2.37
- Q1
- 1.67
- Min
- 0.11
TEVA’s P/S Ratio of 1.80 aligns with the market consensus for the Pharmaceuticals industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
SYK
6.49
Health Care Equipment & Supplies Industry
- Max
- 10.77
- Q3
- 6.04
- Median
- 3.32
- Q1
- 2.31
- Min
- 0.83
SYK’s P/B Ratio of 6.49 is in the upper tier for the Health Care Equipment & Supplies industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
TEVA
2.95
Pharmaceuticals Industry
- Max
- 9.86
- Q3
- 5.28
- Median
- 2.48
- Q1
- 1.57
- Min
- 0.59
TEVA’s P/B Ratio of 2.95 is within the conventional range for the Pharmaceuticals industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | SYK | TEVA |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 46.83 | -- |
| Price-to-Sales Ratio (TTM) | 5.65 | 1.80 |
| Price-to-Book Ratio (MRQ) | 6.49 | 2.95 |
| Price-to-Free Cash Flow Ratio (TTM) | 33.84 | 26.69 |